Literature DB >> 25640730

What is the optimal bone-preserving strategy for patients with Addison's disease?

Paul Lee1, Jerry R Greenfield1.   

Abstract

Addison's disease is associated with low bone mineral density and increased risk of hip fractures. Causes are multifactorial, contributed by underlying adrenocortical hormonal deficiency, associated autoimmune endocrinopathies, electrolyte disturbances and, in some patients, supraphysiologic glucocorticoid replacement. Recent realization of physiologic cortisol production rate has revised downwards glucocorticoid replacement dosages. Meanwhile, new research has emerged suggesting complex interplay between sodium and calcium homoeostasis under the influence of mineralocorticoid and parathyroid hormone that may impact bone health. As the prevalence of Addison's disease is rising, and osteoporosis and fractures are associated with significant morbidity and increased mortality, attention to bone preservation in Addison's disease is of clinical relevance and importance. We suggest an approach to bone health in Addison's disease integrating physiologic adrenocortical hormonal replacement with electrolyte and mineral homoeostasis optimization.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25640730     DOI: 10.1111/cen.12730

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Adrenal crisis after first infusion of zoledronic acid: a case report.

Authors:  M Smrecnik; Z Kavcic Trsinar; T Kocjan
Journal:  Osteoporos Int       Date:  2018-03-28       Impact factor: 4.507

2.  Recurrent Hypokalemia and Adrenal Steroids in Patients With APECED.

Authors:  Joonatan Borchers; Outi Mäkitie; Jarmo Jääskeläinen; Saila Laakso
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

3.  Severe Phenotype of APECED (APS1) Increases Risk for Structural Bone Alterations.

Authors:  Saila Laakso; Joonatan Borchers; Sanna Toiviainen-Salo; Minna Pekkinen; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.